Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
Ajay K. Nooka
No relevant relationships to disclose
Amelia A. Langston
No relevant relationships to disclose
Edmund K. Waller
No relevant relationships to disclose
Leonard T. Heffner
No relevant relationships to disclose
Charise Gleason
No relevant relationships to disclose
Samatha Muppidi
No relevant relationships to disclose
Melanie Watson
No relevant relationships to disclose
Daniela Casbourne
No relevant relationships to disclose
Lawrence Boise
Consultant or Advisory Role - Onyx
Jonathan L. Kaufman
Consultant or Advisory Role - Celgene; Janssen; Millennium; Novartis; Onyx
Research Funding - Celgene; Merck
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi